BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of Dasatinib in Patients With Advanced Solid Tumors
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00162214
- Locations
- ๐บ๐ธ
Lee S. Rosen M.D., Santa Monica, California, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธMd Anderson Cancer Center, Houston, Texas, United States
The Study of Abatacept in Combination With Etanercept
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00162279
- Locations
- ๐บ๐ธ
Local Institution, Glendale, Wisconsin, United States
Abatacept With Methotrexate- Phase IIB
- Conditions
- Interventions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 524
- Registration Number
- NCT00162266
- Locations
- ๐ฌ๐ง
Local Institution, Leeds, Yorkshire, United Kingdom
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT00162292
- Locations
- ๐ฒ๐ฝ
Local Institution, Leon, Guanajuato, Mexico
๐บ๐ธDelray Research Associates, Delray Beach, Florida, United States
๐บ๐ธPhase Iii Clinical Research, Fall River, Massachusetts, United States
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT00162253
- Locations
- ๐บ๐ธ
Local Institution, Dallas, Texas, United States
A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00162448
- Locations
- ๐บ๐ธ
Local Institution, Columbus, Ohio, United States
PPAR - Combination With Metformin
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 534
- Registration Number
- NCT00162240
- Locations
- ๐ฌ๐ง
Local Institution, Swan Lake, United Kingdom
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 248
- Registration Number
- NCT00162123
- Locations
- ๐บ๐ธ
The Angeles Clinic & Research Inst., Los Angeles, California, United States
๐บ๐ธUniversity Of Chicago, Chicago, Illinois, United States
๐บ๐ธIndiana Oncology Hematology Consultants, Indianapolis, Indiana, United States
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 219
- Registration Number
- NCT00135356
- Locations
- ๐ฌ๐ง
Local Institution, London, Greater London, United Kingdom
Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT00135369
- Locations
- ๐ต๐ท
Local Institution, San Juan, Puerto Rico